Literature DB >> 26925809

Plasma Levels of Receptor Interacting Protein Kinase-3 (RIP3), an Essential Mediator of Necroptosis, are Associated with Acute Kidney Injury in Critically Ill Trauma Patients.

Michael G S Shashaty1, John P Reilly, Carrie A Sims, Daniel N Holena, Danielle Qing, Caitlin M Forker, Meghan J Hotz, Nuala J Meyer, Paul N Lanken, Harold I Feldman, Jason D Christie, Nilam S Mangalmurti.   

Abstract

BACKGROUND: Receptor interacting protein kinase-3 (RIP3) is a key mediator of necroptosis, a form of regulated cell death recently implicated in murine models of renal ischemia-reperfusion injury and transfusion-associated endothelial injury. The importance of necroptosis in human AKI is unknown. We hypothesized that plasma RIP3 concentrations would be associated with acute kidney injury (AKI) after severe trauma.
METHODS: We performed a case-control study nested in a prospective cohort of critically ill trauma patients. AKI was defined by AKI Network creatinine criteria within 6 days of presentation. Of 158 cohort subjects, we selected 13 who developed AKI stage 2 or 3, 27 with AKI stage 1, and 40 without AKI. We compared plasma RIP3 concentrations across these groups at presentation and 48 h. Since red blood cell (RBC) transfusion is an AKI risk factor, we also tested the association of RBCs transfused during resuscitation with RIP3 levels.
RESULTS: Median plasma RIP3 concentration rose more than 10-fold from presentation (15.6 (interquartile range 15.6-41.3) pg/mL) to 48 h (164.7 (66.9-300.6) pg/mL; P <0.001). RIP3 concentrations at 48 h were associated with AKI stage (no AKI: 144.8 (58.6-234.9) pg/mL; AKI stage 1: 165.8 (43.0-310.9) pg/mL; AKI stage 2-3: 365.5 (155.1-727.5) pg/mL; P = 0.010) whereas this association was not seen at presentation (P = 0.324). RBC transfusions were also associated with 48-h plasma RIP3 (no RBCs: 99.4 (15.6-166.1) pg/mL; 1-5 units: 182.6 (98.5-274.1) pg/mL; >5 units: 341.8 (150.1-423.8) pg/mL; P <0.001).
CONCLUSIONS: In critically ill trauma patients, plasma levels of the necroptosis mediator RIP3 at 48 h were associated with AKI stage and RBC transfusions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26925809      PMCID: PMC4949076          DOI: 10.1097/SHK.0000000000000596

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  22 in total

1.  African American race, obesity, and blood product transfusion are risk factors for acute kidney injury in critically ill trauma patients.

Authors:  Michael G S Shashaty; Nuala J Meyer; A Russell Localio; Robert Gallop; Scarlett L Bellamy; Daniel N Holena; Paul N Lanken; Sandra Kaplan; Dilek Yarar; Steven M Kawut; Harold I Feldman; Jason D Christie
Journal:  J Crit Care       Date:  2012-05-15       Impact factor: 3.425

Review 2.  A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury.

Authors:  Hernando Gomez; Can Ince; Daniel De Backer; Peter Pickkers; Didier Payen; John Hotchkiss; John A Kellum
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

Review 3.  Regulated cell death in AKI.

Authors:  Andreas Linkermann; Guochun Chen; Guie Dong; Ulrich Kunzendorf; Stefan Krautwald; Zheng Dong
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill.

Authors:  Adam Linder; Chris Fjell; Adeera Levin; Keith R Walley; James A Russell; John H Boyd
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 5.  Pathophysiology of ischemic acute kidney injury.

Authors:  Asif A Sharfuddin; Bruce A Molitoris
Journal:  Nat Rev Nephrol       Date:  2011-03-01       Impact factor: 28.314

6.  Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia.

Authors:  M Schumer; M C Colombel; I S Sawczuk; G Gobé; J Connor; K M O'Toole; C A Olsson; G J Wise; R Buttyan
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

7.  Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury.

Authors:  Andreas Linkermann; Jan H Bräsen; Nina Himmerkus; Shuya Liu; Tobias B Huber; Ulrich Kunzendorf; Stefan Krautwald
Journal:  Kidney Int       Date:  2012-01-11       Impact factor: 10.612

Review 8.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

9.  Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation.

Authors:  Danielle Y Qing; David Conegliano; Michael G S Shashaty; Jeongyun Seo; John P Reilly; G Scott Worthen; Dongeun Huh; Nuala J Meyer; Nilam S Mangalmurti
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  9 in total

Review 1.  Collateral damage: necroptosis in the development of lung injury.

Authors:  Hilary Faust; Nilam S Mangalmurti
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-27       Impact factor: 5.464

2.  RAGE interacts with the necroptotic protein RIPK3 and mediates transfusion-induced danger signal release.

Authors:  Hilary Faust; Lk Metthew Lam; Meghan J Hotz; Danielle Qing; Nilam S Mangalmurti
Journal:  Vox Sang       Date:  2020-07-07       Impact factor: 2.144

3.  RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.

Authors:  Angara Sureshbabu; Edwin Patino; Kevin C Ma; Kristian Laursen; Eli J Finkelsztein; Oleh Akchurin; Thangamani Muthukumar; Stefan W Ryter; Lorraine Gudas; Augustine M K Choi; Mary E Choi
Journal:  JCI Insight       Date:  2018-06-07

Review 4.  Necroptosis: a crucial pathogenic mediator of human disease.

Authors:  Mary E Choi; David R Price; Stefan W Ryter; Augustine M K Choi
Journal:  JCI Insight       Date:  2019-08-08

5.  Circulating RIPK3 levels are associated with mortality and organ failure during critical illness.

Authors:  Kevin C Ma; Edward J Schenck; Ilias I Siempos; Suzanne M Cloonan; Eli J Finkelsztein; Maria A Pabon; Clara Oromendia; Karla V Ballman; Rebecca M Baron; Laura E Fredenburgh; Angelica Higuera; Jin Young Lee; Chi Ryang Chung; Kyeongman Jeon; Jeong Hoon Yang; Judie A Howrylak; Jin-Won Huh; Gee Young Suh; Augustine Mk Choi
Journal:  JCI Insight       Date:  2018-07-12

6.  Plasma levels of receptor interacting protein kinase-3 correlated with coronary artery disease.

Authors:  Xiao-Min Hu; Xi Chen; Hai-Yu Pang; Hong-Hong Liu; Pei-Pei Chen; Jing-Lin Shi; Si Tang; Zhi-Hong Wu; Shu-Yang Zhang
Journal:  Chin Med J (Engl)       Date:  2019-06-20       Impact factor: 2.628

7.  Plasma levels of receptor-interacting protein kinase 3 is associated with postoperative acute kidney injury in acute DeBakey type I aortic dissection.

Authors:  Lei Wang; Guodong Zhong; Hao Zhou; Xiaochai Lv; Yi Dong; Xiaoli Wang; Xiaofu Dai; Yanfang Xu; Liangwan Chen
Journal:  J Cardiothorac Surg       Date:  2022-03-15       Impact factor: 1.637

8.  The role of RIPK1 mediated cell death in acute on chronic liver failure.

Authors:  Takayuki Kondo; Stewart Macdonald; Cornelius Engelmann; Abeba Habtesion; Jane Macnaughtan; Gautam Mehta; Rajeshwar P Mookerjee; Nathan Davies; Marco Pavesi; Richard Moreau; Paolo Angeli; Vicente Arroyo; Fausto Andreola; Rajiv Jalan
Journal:  Cell Death Dis       Date:  2021-12-17       Impact factor: 9.685

9.  Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.

Authors:  Bing Wang; Jian Li; Hong-Mei Gao; Ying-Hong Xing; Zhu Lin; Hong-Jie Li; Yong-Qiang Wang
Journal:  Oncotarget       Date:  2017-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.